Literature DB >> 25533477

Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.

Yat Fung Shea1, Joyce Ha1, Leung-Wing Chu1,2.   

Abstract

BACKGROUND: There has been no previous Chinese study that differentiated the clinical symptoms among biomarker-confirmed Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). The objective of this study was to compare the cognitive, behavioural, and neuropsychiatric symptoms in biomarker-confirmed AD, DLB, and FTD patients.
METHODS: We recruited 30 patients (14 AD, 7 DLB, 9 FTD) who presented to the memory clinic at Queen Mary Hospital from 1 January 2007 to 31 December 2013. AD was diagnosed according to the National Institution of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria with cerebrospinal fluid biomarkers (tau, phosphorylated tau, and amyloid β-42) fulfilling locally determined cut-off values for AD. DLB was diagnosed based on the McKeith diagnostic criteria. The behavioural variant of FTD was diagnosed based on the revised diagnostic criteria proposed by the International bvFTD Criteria Consortium, and language variant FTD was diagnosed based on the latest published criteria. In addition, patients with DLB and FTD had typical imaging features on single-photon emission computed tomography or (18) fludeoxyglucose-positron emission tomography, either with or without Pittsburgh Compound B imaging, which supported their diagnoses. Data on patient characteristics including demographics, presenting clinical features, Mini-Mental State Examination, clinical dementia ratings, and neuropsychiatry inventory scores were collected.
RESULTS: There were no differences in age, education level, dementia severity, and duration of symptoms before presentation among the three subgroups of patients. All patients had amnesia symptoms, which were not statistically significant. Apraxia was most common in AD. While 83% of the patients were affected by behavioural and neuropsychiatric symptoms of dementia, behavioural disinhibition and decline in executive function were most common in FTD patients. Recurrent hallucinations, fluctuation of consciousness, parkinsonism, and rapid eye movement sleep behaviour disorder were most common in DLB.
CONCLUSION: Memory impairment and apathy are not useful discriminative symptoms in diagnosing AD, DLB, and FTD. Apraxia favours AD. Hallucinations, particularly well-formed visual hallucinations, favour DLB. Overall, behavioural and neuropsychiatric symptoms of dementia symptoms are common among the three groups of dementia patients.
© 2014 The Authors. Psychogeriatrics © 2014 Japanese Psychogeriatric Society.

Entities:  

Keywords:  Alzheimer's disease; Lewy body disease; biomarker; frontotemporal dementia

Mesh:

Substances:

Year:  2014        PMID: 25533477     DOI: 10.1111/psyg.12103

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN: 1346-3500            Impact factor:   2.440


  3 in total

Review 1.  RBD and Neurodegenerative Diseases.

Authors:  Haiyang Jiang; Jinsha Huang; Yan Shen; Shiyi Guo; Luxi Wang; Chao Han; Ling Liu; Kai Ma; Yun Xia; Jie Li; Xiaoyun Xu; Nian Xiong; Tao Wang
Journal:  Mol Neurobiol       Date:  2016-03-31       Impact factor: 5.590

2.  Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis.

Authors:  Charlotte Louise Eversfield; Llwyd David Orton
Journal:  Psychol Med       Date:  2018-11-26       Impact factor: 7.723

3.  REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment.

Authors:  Stuart J McCarter; Grace M Tabatabai; Ho-Yann Jong; David J Sandness; Paul C Timm; Katie L Johnson; Allison R McCarter; Rodolfo Savica; Prashanthi Vemuri; Mary M Machulda; Kejal Kantarci; Michelle M Mielke; Bradley F Boeve; Michael H Silber; Erik K St Louis
Journal:  Neurology       Date:  2019-12-12       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.